290 related articles for article (PubMed ID: 16367903)
1. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes.
Matsubara D; Niki T; Ishikawa S; Goto A; Ohara E; Yokomizo T; Heizmann CW; Aburatani H; Moriyama S; Moriyama H; Nishimura Y; Funata N; Fukayama M
Cancer Sci; 2005 Dec; 96(12):844-57. PubMed ID: 16367903
[TBL] [Abstract][Full Text] [Related]
2. Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.
Lee OJ; Hong SM; Razvi MH; Peng D; Powell SM; Smoklin M; Moskaluk CA; El-Rifai W
Neoplasia; 2006 Oct; 8(10):843-50. PubMed ID: 17032501
[TBL] [Abstract][Full Text] [Related]
3. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis.
Feng G; Xu X; Youssef EM; Lotan R
Cancer Res; 2001 Nov; 61(21):7999-8004. PubMed ID: 11691825
[TBL] [Abstract][Full Text] [Related]
4. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.
Matsumoto K; Irie A; Satoh T; Ishii J; Iwabuchi K; Iwamura M; Egawa S; Baba S
Urology; 2007 Sep; 70(3):602-7. PubMed ID: 17688917
[TBL] [Abstract][Full Text] [Related]
5. Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3.
Naz S; Bashir M; Ranganathan P; Bodapati P; Santosh V; Kondaiah P
Carcinogenesis; 2014 Jan; 35(1):14-23. PubMed ID: 23996929
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of altered S100A2 expression in gastric cancer.
Zhao Y; Zhang TB; Wang Q
Oncol Rep; 2013 Apr; 29(4):1556-62. PubMed ID: 23337980
[TBL] [Abstract][Full Text] [Related]
7. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression.
Miyazaki N; Abe Y; Oida Y; Suemizu H; Nishi M; Yamazaki H; Iwasaki M; Inoue H; Ueyama Y; Nakamura M
Int J Oncol; 2006 Jun; 28(6):1369-74. PubMed ID: 16685438
[TBL] [Abstract][Full Text] [Related]
8. Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma.
Luo J; Zhu Y; Yang G; Gong L; Wang B; Liu H
Diagn Cytopathol; 2011 Oct; 39(10):752-7. PubMed ID: 20949468
[TBL] [Abstract][Full Text] [Related]
9. S100 calcium-binding protein A4 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.
Zhao Y; Zhang T; Wang Q
Oncol Rep; 2013 Jul; 30(1):111-8. PubMed ID: 23612849
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis.
Ohuchida K; Mizumoto K; Miyasaka Y; Yu J; Cui L; Yamaguchi H; Toma H; Takahata S; Sato N; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
J Pathol; 2007 Nov; 213(3):275-82. PubMed ID: 17940995
[TBL] [Abstract][Full Text] [Related]
11. Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development.
Shimada A; Kano J; Ishiyama T; Okubo C; Iijima T; Morishita Y; Minami Y; Inadome Y; Shu Y; Sugita S; Takeuchi T; Noguchi M
Cancer Sci; 2005 Oct; 96(10):668-75. PubMed ID: 16232198
[TBL] [Abstract][Full Text] [Related]
12. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
13. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
14. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer.
Yonemura Y; Endou Y; Kimura K; Fushida S; Bandou E; Taniguchi K; Kinoshita K; Ninomiya I; Sugiyama K; Heizmann CW; Schafer BW; Sasaki T
Clin Cancer Res; 2000 Nov; 6(11):4234-42. PubMed ID: 11106237
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma.
Gupta S; Hussain T; MacLennan GT; Fu P; Patel J; Mukhtar H
J Clin Oncol; 2003 Jan; 21(1):106-12. PubMed ID: 12506178
[TBL] [Abstract][Full Text] [Related]
16. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.
Smith SL; Gugger M; Hoban P; Ratschiller D; Watson SG; Field JK; Betticher DC; Heighway J
Br J Cancer; 2004 Oct; 91(8):1515-24. PubMed ID: 15467767
[TBL] [Abstract][Full Text] [Related]
17. Regulation of S100A2 expression by TGF-β-induced MEK/ERK signalling and its role in cell migration/invasion.
Naz S; Ranganathan P; Bodapati P; Shastry AH; Mishra LN; Kondaiah P
Biochem J; 2012 Oct; 447(1):81-91. PubMed ID: 22747445
[TBL] [Abstract][Full Text] [Related]
18. Frequent polymorphic variations but rare tumour specific mutations of the S100A2 on 1q21 in non-small cell lung cancer.
Strazisar M; Rott T; Glavac D
Lung Cancer; 2009 Mar; 63(3):354-9. PubMed ID: 18656279
[TBL] [Abstract][Full Text] [Related]
19. Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway.
Hibi K; Fujitake S; Takase T; Kodera Y; Ito K; Akiyama S; Shirane M; Nakao A
Clin Cancer Res; 2003 Sep; 9(11):4282-5. PubMed ID: 14519656
[TBL] [Abstract][Full Text] [Related]
20. S100A2 induces metastasis in non-small cell lung cancer.
Bulk E; Sargin B; Krug U; Hascher A; Jun Y; Knop M; Kerkhoff C; Gerke V; Liersch R; Mesters RM; Hotfilder M; Marra A; Koschmieder S; Dugas M; Berdel WE; Serve H; Müller-Tidow C
Clin Cancer Res; 2009 Jan; 15(1):22-9. PubMed ID: 19118029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
